RYTMRhythm Pharmaceuticals, Inc.
$90.85-5.4% 1Y
$90.85
$75.8252 weeks$117.62
RYTM in its own filings
Nothing in RYTM's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
182
Events found in the filings · across 834 filings · the record starts in 2015
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 4, 2026
Most recent filing · Form 10-Q
- Record starts
- Nov 10, 2015
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 3, 2026
- SEC comment-letter activity14 occurrences
- 2021-11-10
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026The presentation is available in the “Events and Presentations” portion of the Company’s website at ir.rhythmtx.com.Earnings release · Form 8-K
- Jun 15, 2026The presentation is available in the “Events and Presentations” portion of the Company’s website at ir.rhythmtx.com.Regulation FD disclosure · Form 8-K
- Apr 3, 2026Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers On April 1, 2026, the Board of Directors (the “Board”) of Rhythm Pharmaceuticals, Inc. (the “Company”) elected Kimberly J. Popovits as a non-employee director of the …Director or officer change · Form 8-K
- Mar 26, 2026On March 26, 2026, Rhythm announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending to expand the current marketing authorization for IMCIVREE ® (setmelanotide) to include the treatment of obesity and the control of hunger in …Regulation FD disclosure · Form 8-K
- Mar 20, 2026The presentation is available in the “Events and Presentations” portion of the Company’s website at ir.rhythmtx.com.Regulation FD disclosure · Form 8-K
- Mar 16, 2026The presentation is available in the “Events and Presentations” portion of the Company’s website at ir.rhythmtx.com.Regulation FD disclosure · Form 8-K
- Mar 2, 2026On March 1, 2026, Rhythm announced additional data from its global Phase 3 TRANSCEND trial of setmelanotide in patients with acquired hypothalamic obesity, which are summarized below.Regulation FD disclosure · Form 8-K
- Jan 9, 2026On January 9, 2026, the Company announced preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an increase of 11% percent on a sequential basis from the third quarter of 2025.Earnings release · Form 8-K
- Dec 19, 2025On December 16, 2025, Camille L. Bedrosian, M.D. notified the Board of Directors (the “Board”) of Rhythm Pharmaceuticals, Inc. (the “Company”) of her decision to resign from the Board, effective immediately.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…